FDA warned Glicerinas Industriales over CGMP failures in repackaged glycerin and propylene glycol, including DEG/EG testing and particulate contamination.
What happened
FDA inspected the Zapopan facility from May 8 to 12, 2023. It found the company failed to test incoming high-risk drugs such as glycerin for DEG/EG and failed to investigate particulate contamination (colored particles, insects, hair, fibers) in repackaged glycerin and propylene glycol; the company released contaminated lots without adequate investigation. FDA also placed the firm on Import Alert 66-40.
What FDA found
Failed to test the identity of each batch of incoming production material and to qualify suppliers before relying on their certificates of analysis.
FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)Failed to adequately test high-risk glycerin for diethylene glycol (DEG) and ethylene glycol (EG) contamination.
FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)Failed to investigate deviations from quality specifications, including particulate contamination in repackaged drugs.
FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)Did not reject lots contaminated with colored particulates, insects, hair, and fibers, and released them to customers without a full root-cause investigation.
FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)Failed to assess the safety risk of contaminated drugs released to customers, including customer notification.
FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)Failed to implement corrective and preventive action until after FDA cited the firm.
FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
What FDA wants
FDA tells the company to respond in writing within 15 working days with corrective actions, and to provide DEG/EG test results from retained high-risk lots within 30 calendar days, plus independent reviews and action plans. FDA also recommends a qualified CGMP consultant perform a six-system audit.
Who should pay attention
- drug manufacturers that buy API or excipients from this repackager
- brands using glycerin or propylene glycol in finished pharmaceuticals
- quality teams managing supplier qualification and incoming material testing
This is a summary. Read the original letter on fda.gov.